[go: up one dir, main page]

BG63048B1 - Цитостатици, модифицирани с въглехидрати - Google Patents

Цитостатици, модифицирани с въглехидрати Download PDF

Info

Publication number
BG63048B1
BG63048B1 BG101892A BG10189297A BG63048B1 BG 63048 B1 BG63048 B1 BG 63048B1 BG 101892 A BG101892 A BG 101892A BG 10189297 A BG10189297 A BG 10189297A BG 63048 B1 BG63048 B1 BG 63048B1
Authority
BG
Bulgaria
Prior art keywords
methanol
mmol
methylene chloride
tlc
methyl
Prior art date
Application number
BG101892A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG101892A (en
Inventor
Hans - Georg LERCHEN
Dem Bruch Karsten Von
Uwe Petersen
Joerg Baumgarten
Norbert Piel
Horst-Peter Antonicek
Walter Weichel
Michael Sperzel
Klaus Bremm
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of BG101892A publication Critical patent/BG101892A/xx
Publication of BG63048B1 publication Critical patent/BG63048B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Pyrane Compounds (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
BG101892A 1995-04-04 1997-09-16 Цитостатици, модифицирани с въглехидрати BG63048B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19512484A DE19512484A1 (de) 1995-04-04 1995-04-04 Kohlenhydratmodifizierte Cytostatika
PCT/EP1996/001279 WO1996031532A1 (de) 1995-04-04 1996-03-22 Kohlenhydratmodifizierte cytostatika

Publications (2)

Publication Number Publication Date
BG101892A BG101892A (en) 1998-05-29
BG63048B1 true BG63048B1 (bg) 2001-02-28

Family

ID=7758679

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101892A BG63048B1 (bg) 1995-04-04 1997-09-16 Цитостатици, модифицирани с въглехидрати

Country Status (27)

Country Link
US (1) US6271342B1 (et)
EP (1) EP0819135B1 (et)
JP (1) JPH11502860A (et)
KR (1) KR19980703591A (et)
CN (1) CN1185786A (et)
AT (1) ATE186738T1 (et)
AU (1) AU713466B2 (et)
BG (1) BG63048B1 (et)
BR (1) BR9604825A (et)
CA (1) CA2217164A1 (et)
CZ (1) CZ291098B6 (et)
DE (2) DE19512484A1 (et)
DK (1) DK0819135T3 (et)
EE (1) EE03619B1 (et)
ES (1) ES2140078T3 (et)
GR (1) GR3032605T3 (et)
HU (1) HUP9800513A3 (et)
IS (1) IS1822B (et)
MX (1) MX9707613A (et)
NO (1) NO974564L (et)
NZ (1) NZ305855A (et)
PL (1) PL183574B1 (et)
RU (1) RU2170234C2 (et)
SK (1) SK281785B6 (et)
TW (1) TW384290B (et)
UA (1) UA61054C2 (et)
WO (1) WO1996031532A1 (et)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2267328A1 (en) * 1996-09-30 1998-04-09 Bayer Aktiengesellschaft Glycoconjugates from modified camptothecin derivates (20-o-linkage)
DE19640970A1 (de) * 1996-10-04 1998-04-16 Bayer Ag Modifizierte Cytostatika
JP3101710B2 (ja) 1997-02-28 2000-10-23 工業技術院長 硫酸化オリゴ糖化合物
ID23424A (id) * 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
US6387928B1 (en) 1997-09-15 2002-05-14 The Procter & Gamble Co. Antimicrobial quinolones, their compositions and uses
AU735186B2 (en) 1997-09-15 2001-07-05 Warner Chilcott Company, Llc Antimicrobial quinolones, their compositions and uses
US6613879B1 (en) * 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
DE10005275A1 (de) * 2000-02-07 2001-08-09 Bayer Ag Neuartige Glycokonjugate
US7220824B1 (en) * 2000-08-28 2007-05-22 Bayer Aktiengesellschaft Integrin-mediated drug targeting
EP1219634A1 (en) * 2000-12-27 2002-07-03 Bayer Aktiengesellschaft Cytostatic-glycoconjugates having specifically cleavable peptidic linking units
EP1238678A1 (en) * 2001-03-08 2002-09-11 Bayer Aktiengesellschaft Enzyme-activated cytostatic conjugates with integrin ligands
US20050037423A1 (en) * 2001-11-09 2005-02-17 Bayer Healthcare Ag Isotopycally coded affinity marker 2
US7199149B2 (en) * 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
EP1718677B1 (en) 2003-12-19 2012-04-18 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
EP1999125A2 (en) 2006-03-28 2008-12-10 The Procter and Gamble Company A coupling process for preparing quinolone intermediates
EP1999106B1 (en) 2006-03-28 2012-06-27 TaiGen Biotechnology Co., Ltd. A hydride reduction process for preparing quinolone intermediates
AU2007230630B2 (en) 2006-03-28 2012-12-20 Taigen Biotechnology Co., Ltd Malate salts, and polymorphs of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
HK1245280A1 (zh) 2015-01-06 2018-08-24 Immunovaccine Technologies Inc. 脂质a模拟物、其制备方法和用途
SMT202400223T1 (it) 2015-11-25 2024-07-09 Ligachem Biosciences Inc Coniugati comprendenti gruppi autoimmolativi e metodi correlati ad essi
KR102847350B1 (ko) 2015-11-25 2025-08-19 주식회사 리가켐바이오사이언스 분지된 링커를 포함하는 항체-약물 접합체 및 이의 제조방법
JP7664680B2 (ja) 2017-03-29 2025-04-18 リガケム バイオサイエンシズ， インク． ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物
SG11202010443WA (en) 2018-05-09 2020-11-27 Legochem Biosciences Inc Compositions and methods related to anti-cd19 antibody drug conjugates
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
JP2024537169A (ja) * 2021-10-06 2024-10-10 サムヤン コーポレイション 飽和フロジオキシン誘導体化合物及びその二次電池用添加剤としての使用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5977356A (ja) * 1982-06-30 1984-05-02 Fuji Photo Film Co Ltd 螢光アツセイ用多層分析要素およびそれを用いる螢光アツセイ法
DE3611194A1 (de) 1986-04-04 1987-10-08 Bayer Ag Cancerostatisches mittel
DE3889956T2 (de) * 1987-03-26 1994-12-22 Neorx Corp Metall-Radionuklid-markierte Proteine und Glykoproteine zur Diagnose und Therapie.
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4980343A (en) * 1988-10-27 1990-12-25 Bayer Aktiengesellschaft Aminooxodihydroisoindoloquinazoline carcinostatic agents
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
NZ236393A (en) * 1989-12-13 1992-05-26 Lilly Co Eli N-alkylated glycopeptide derivatives prepared from antibiotics a82846 series and pa-42867-a; pharmaceutical compositions
US5160727A (en) * 1990-02-13 1992-11-03 Warner-Lambert Company Tumor cell sensitization method using quinazolinedione derivatives
US6075121A (en) 1990-05-15 2000-06-13 Chiron Corporation Modified peptide and peptide libraries with protease resistance, derivatives thereof and methods of producing and screening such
US5420297A (en) 1990-10-24 1995-05-30 Fujisawa Pharmaceutical Co., Ltd. Peptides having substance P antagonistic activity
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
DE4106101A1 (de) * 1991-02-27 1992-09-03 Bayer Ag Fucose-markierte cytostatika
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
FR2676058B1 (fr) 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
DE4120646A1 (de) 1991-06-22 1992-12-24 Bayer Ag 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate
ES2137937T3 (es) 1991-11-29 2000-01-01 Hoechst Ag Peptidos con efecto del tipo de insulina.
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
FI933472A7 (fi) 1992-08-07 1994-02-08 Sankyo Co Peptider med foermaoga att inhibera effekten av HIV-proteas, deras framstaellning och terapeutiska anvaendning
US5872207A (en) 1992-09-04 1999-02-16 Sanofi Pharmaceuticals, Inc. N-terminal-marked peptides immobilized on glass beads and method of preparation and method of use thereof
IL106998A0 (en) 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US5576298A (en) 1992-11-30 1996-11-19 Research And Development Institute, Inc. At Montana State University Peptides from pseudomonas syringae possessing broad-spectrum antibiotic activity
SE9300012D0 (sv) 1993-01-05 1993-01-05 Astra Ab New peptides
US5750648A (en) 1993-08-20 1998-05-12 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
GB9320781D0 (en) 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
WO1995010296A1 (en) * 1993-10-12 1995-04-20 Glycomed Incorporated A library of glyco-peptides useful for identification of cell adhesion inhibitors
US5610145A (en) 1994-04-15 1997-03-11 Warner-Lambert Company Tachykinin antagonists
US5780589A (en) 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
FR2729668A1 (fr) 1995-01-23 1996-07-26 Adir Nouveaux derives de mercaptoalcanoyldipeptides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5677286A (en) * 1995-04-27 1997-10-14 The University Of Michigan Glycosylated analogs of camptothecin
US6143931A (en) 1997-04-16 2000-11-07 Arqule, Inc. Synthesis and use of α-ketoamide derivatives and arrays

Also Published As

Publication number Publication date
EE9700258A (et) 1998-04-15
EP0819135A1 (de) 1998-01-21
BR9604825A (pt) 1999-01-05
SK281785B6 (sk) 2001-07-10
IS4562A (is) 1997-09-18
UA61054C2 (en) 2003-11-17
PL322681A1 (en) 1998-02-16
HUP9800513A2 (hu) 1998-06-29
AU5397696A (en) 1996-10-23
GR3032605T3 (en) 2000-05-31
RU2170234C2 (ru) 2001-07-10
DE59603678D1 (de) 1999-12-23
AU713466B2 (en) 1999-12-02
SK134597A3 (en) 1998-05-06
HUP9800513A3 (en) 1998-09-28
PL183574B1 (pl) 2002-06-28
MX9707613A (es) 1997-12-31
CZ314397A3 (cs) 1998-01-14
ES2140078T3 (es) 2000-02-16
US6271342B1 (en) 2001-08-07
IS1822B (is) 2002-10-01
CA2217164A1 (en) 1996-10-10
KR19980703591A (ko) 1998-11-05
NO974564D0 (no) 1997-10-02
NZ305855A (en) 1999-11-29
ATE186738T1 (de) 1999-12-15
DE19512484A1 (de) 1996-10-17
EE03619B1 (et) 2002-02-15
BG101892A (en) 1998-05-29
CN1185786A (zh) 1998-06-24
NO974564L (no) 1997-11-25
CZ291098B6 (cs) 2002-12-11
DK0819135T3 (da) 2000-05-08
WO1996031532A1 (de) 1996-10-10
JPH11502860A (ja) 1999-03-09
EP0819135B1 (de) 1999-11-17
TW384290B (en) 2000-03-11

Similar Documents

Publication Publication Date Title
BG63048B1 (bg) Цитостатици, модифицирани с въглехидрати
EP1447099B1 (de) Antineoplastisch wirkende Polyethylenkonjugate zytostatischer Verbindungen und diese enthaltende Arzneimittel
DE69637383T2 (de) Cytotoxinkonjugate umfassend dipeptide
US6156754A (en) Glycoconjugates of modified camptothecin derivatives (A-or B-ring linkage)
JP7620991B2 (ja) 標的送達及び活性化した免疫刺激性複合体の調製と使用
EP1619210A1 (en) DDS compounds and method for assaying the same
DE4436164A1 (de) Neue Kohlenhydratkonjugate als Inhibitoren der Zelladhäsion
DE102009051799B4 (de) Bifunktionale Prodrugs und Drugs
EA000006B1 (ru) Производные полипирролкарбоксамидонафталина, способ их получения и их применение
CN104520309A (zh) 抗真菌抗生素两性霉素b的n-取代第二代衍生物及其制备方法和应用
HU210744B (en) Process to prepare novel ganglioside derivs. and pharmaceutical compns. contg. them
CA2267328A1 (en) Glycoconjugates from modified camptothecin derivates (20-o-linkage)
US20020173468A1 (en) Modified cytostatic agents
WO2001058932A1 (de) Glycokonjugate von cytostatika
WO2005026169A1 (en) Ceratamines a and b, and analogues, syntheses and pharmaceutical compositions thereof
IL119334A (en) Carbohydrate modified cytostatics and medicaments containing them
HRP960440A2 (en) Sugar-modified cytostatics
DE10005275A9 (de) Neuartige glycokonjugate
RU2184122C2 (ru) Гликоконъюгаты 20(s)-камптотецина
CA3260561A1 (en) NEW COMPOUND LOCATOR AND CONJUGATED LIGAND-MEDICINE ASSOCIATE
CZ401799A3 (cs) Glykokonjugáty 20(S)-camptothecinu, způsob jejich výroby, jejich použití a léčiva tyto látky obsahující